Trade Kyntra Bio Inc - KYNB CFD

Trading Conditions

• Type: CFD
• Spread: 0.26
• Long position overnight funding adjustment: -0.02151%
• Short position overnight funding adjustment: -0.00071%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 6.72
• Open: 6.68
• 1-Year Change: 1864.71%
• Day's Range: 6.46 - 6.68

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.